New Enzyme Products Launched at the AACR Annual Conference with Higher Specific Collagenase and Caseinase Activities.
LAKEWOOD, NJ (April 4, 2017) – Worthington announced today at the American Association of Cancer Research (AACR) in Washington, DC, the release of the new 2017 – 2018 Enzyme and Biochemical Catalog for biochemistry, cell biology, molecular biology and bioprocessing applications.
As an enzyme specialty company with a solid 70-year history, the Worthington name has become synonymous with the term “primary producer”. New products highlighted in the guide include Celase® GMP enzyme to support pre-clinical research and collagenase type 6 and type 7 for primary cell isolation applications requiring strong digestive capabilities.
“We are proud to release our new catalog focusing on cell and molecular biology, tissue dissociation and protein research,” said Jim Zacka, vice president at Worthington. “Announcing its availability at the AACR conference this week, shows the company’s continuing commitment to keep pace with industry trends as more and more studies move from medical research to the clinic”.
The new Worthington catalog is available in both print and digital formats. To request a copy, go to http://www.worthington-biochem.com/mailingList/request.php
About Worthington Biochemical Corporation
Founded in 1947, Worthington Biochemical Corporation is an industry leader in the development and production of high quality purified enzymes, proteins, nucleic acids and cell isolation kits for life science research, diagnostics and biotechnology applications. An ISO9001 Certified, primary manufacturer Worthington meets enzyme requirements from research to scale-up bulk bioprocessing and OEM applications. Worthington Biochemical Corporation is a privately held company, headquartered in Lakewood, NJ and has worldwide distribution through a network of exclusive distributors.
